Savara, Inc. (SVRA)
NMS · Healthcare · Biotechnology
$5.26
-0.19%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.07B
Exchange
NMS
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -31.4M | -30.3M | -33.4M | -38.1M |
| Net Income | -30.4M | -29.6M | -32.2M | -37.3M |
| Diluted EPS | $-0.14 | $-0.14 | $nan | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -38.0M | -59.2M | -102.4M | -122.8M |
| Net Income | -38.1M | -54.7M | -95.9M | -118.8M |
| Diluted EPS | $-0.25 | $-0.33 | $-0.48 | $-0.53 |